Author:
Sparrow Erin,Adetifa Ifedayo,Chaiyakunapruk Nathorn,Cherian Thomas,Fell Deshayne B.,Graham Barney S.,Innis Bruce,Kaslow David C.,Karron Ruth A.,Nair Harish,Neuzil Kathleen M.,Saha Samir,Smith Peter G.,Srikantiah Padmini,Were Fred,Zar Heather J.,Feikin Daniel
Funder
World Health Organization
Bill and Melinda Gates Foundation
Subject
Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine
Reference23 articles.
1. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study;Shi;Lancet,2017
2. Does respiratory syncytial virus lower respiratory illness in early life cause recurrent wheeze of early childhood and asthma? Critical review of the evidence and guidance for future studies from a World Health Organization-sponsored meeting;Driscoll;Vaccine,2020
3. WHO. Meeting of the Strategic Advisory Group of Experts on immunization, April 2016– conclusions and recommendations. Weekly epidemiological record, 27 May 2016; available here: (accessed 16 August 2021).
4. PATH RSV Vaccine and mAb Snapshot April 2021 (www.path.org/resources/rsv-vaccine-and-mab-snapshot/, accessed on 18 August 2021).
5. Astra Zeneca Press Release 26 April 2021, Nirsevimab MELODY Phase III trial met primary endpoint of reducing RSV lower respiratory tract infections in healthy infants. (available here: https://www.astrazeneca.com/media-centre/press-releases/2021/nirsevimab-phase-iii-trial-met-primary-endpoint.html, accessed on 19 August 2021.
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献